EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access

SARS-CoV-2 Infection and Development of Islet Autoimmunity in Early Childhood

Marija Lugar, Anne Eugster, Peter Achenbach, Thekla von dem Berge, Reinhard Berner, Rachel E J Besser, Kristina Casteels, Helena Elding Larsson, Gita Gemulla, Olga Kordonouri, Annett Lindner, Markus Lundgren und 9 weitere

JAMA · 26.09.2023 · 330 (12) · 1151

DOI: 10.1001/jama.2023.16348 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift JAMA, erschienen am 26.09.2023. Verfasst von Marija Lugar und 20 weiteren Autor:innen. Beteiligte Einrichtung: Technische Universität Dresden, Center for Regenerative Therapies Dresden, Dresden, Germany. Hauptthemen laut MEDLINE: COVID-19, Diabetes Mellitus, Type 1, Islets of Langerhans. Die Arbeit wurde bisher 38-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Wellcome Trust.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance The incidence of diabetes in childhood has increased during the COVID-19 pandemic. Elucidating whether SARS-CoV-2 infection is associated with islet autoimmunity, which precedes type 1 diabetes onset, is relevant to disease etiology and future childhood diabetes trends.

Objective

To determine whether there is a temporal relationship between SARS-CoV-2 infection and the development of islet autoimmunity in early childhood. Design, Setting, and Participants Between February 2018 and March 2021, the Primary Oral Insulin Trial, a European multicenter study, enrolled 1050 infants (517 girls) aged 4 to 7 months with a more than 10% genetically defined risk of type 1 diabetes. Children were followed up through September 2022. Exposure SARS-CoV-2 infection identified by SARS-CoV-2 antibody development in follow-up visits conducted at 2- to 6-month intervals until age 2 years from April 2018 through June 2022. Main Outcomes and Measures The development of multiple (≥2) islet autoantibodies in follow-up in consecutive samples or single islet antibodies and type 1 diabetes. Antibody incidence rates and risk of developing islet autoantibodies were analyzed.

Results

Consent was obtained for 885 (441 girls) children who were included in follow-up antibody measurements from age 6 months. SARS-CoV-2 antibodies developed in 170 children at a median age of 18 months (range, 6-25 months). Islet autoantibodies developed in 60 children. Six of these children tested positive for islet autoantibodies at the same time as they tested positive for SARS-CoV-2 antibodies and 6 at the visit after having tested positive for SARS-CoV-2 antibodies. The sex-, age-, and country-adjusted hazard ratio for developing islet autoantibodies when the children tested positive for SARS-CoV-2 antibodies was 3.5 (95% CI, 1.6-7.7; P = .002). The incidence rate of islet autoantibodies was 3.5 (95% CI, 2.2-5.1) per 100 person-years in children without SARS-CoV-2 antibodies and 7.8 (95% CI, 5.3-19.0) per 100 person-years in children with SARS-CoV-2 antibodies ( P = .02). Islet autoantibody risk in children with SARS-CoV-2 antibodies was associated with younger age (<18 months) of SARS-CoV-2 antibody development (HR, 5.3; 95% CI, 1.5-18.3; P = .009). Conclusion and relevance In young children with high genetic risk of type 1 diabetes, SARS-CoV-2 infection was temporally associated with the development of islet autoantibodies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19Diabetes Mellitus, Type 1Islets of LangerhansChild, PreschoolFemaleHumansInfantAntibodies, ViralAutoantibodiesAutoimmunityPandemicsSARS-CoV-2MaleGenetic Predisposition to Disease

Substanzen

Antibodies, ViralAutoantibodies

Autor:innen und Institutionen

  • Technische Universität Dresden, Center for Regenerative Therapies Dresden, Dresden, Germany.
  • Institute of Diabetes Research, Helmholtz Munich, German Center for Environmental Health, Munich, Germany.
  • Forschergruppe Diabetes, School of Medicine, Klinikum rechts der Isar, Technical University Munich, Munich, Germany.
  • Forschergruppe Diabetes e.V. at Helmholtz Munich, German Research Center for Environmental Health, Munich, Germany.
  • Kinder-und Jugendkrankenhaus AUF DER BULT, Hannover, Germany.
  • Department of Pediatrics, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.

Förderung

  • Wellcome Trust

Zitieren

APA

Lugar, M., Eugster, A., Achenbach, P., von dem Berge, T., Berner, R., Besser, R. E. J., Casteels, K., Elding Larsson, H., Gemulla, G., Kordonouri, O., Lindner, A., Lundgren, M., Müller, D., Oltarzewski, M., Rochtus, A., Scholz, M., Szypowska, A., Todd, J. A., Ziegler, A. G., …, & GPPAD Study Group (2023). SARS-CoV-2 Infection and Development of Islet Autoimmunity in Early Childhood. JAMA, 330(12), 1151. https://doi.org/10.1001/jama.2023.16348

Vancouver

Lugar M, Eugster A, Achenbach P, von dem Berge T, Berner R, Besser REJ, et al. SARS-CoV-2 Infection and Development of Islet Autoimmunity in Early Childhood. JAMA. 2023;330(12):1151. doi:10.1001/jama.2023.16348

BibTeX
@article{Lugar2023,
  author = {Lugar, Marija and Eugster, Anne and Achenbach, Peter and von dem Berge, Thekla and Berner, Reinhard and Besser, Rachel E J and Casteels, Kristina and Elding Larsson, Helena and Gemulla, Gita and Kordonouri, Olga and Lindner, Annett and Lundgren, Markus and Müller, Denise and Oltarzewski, Mariusz and Rochtus, Anne and Scholz, Marlon and Szypowska, Agnieszka and Todd, John A and Ziegler, Anette-Gabriele and Bonifacio, Ezio and GPPAD Study Group, GPPAD Study Group},
  title = {SARS-CoV-2 Infection and Development of Islet Autoimmunity in Early Childhood},
  journal = {JAMA},
  year = {2023},
  volume = {330},
  number = {12},
  pages = {1151},
  doi = {10.1001/jama.2023.16348}
}
Kostenlos starten →